Amesite Inc.
For the period ended Jun 30, 2026. Filed Sep 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 23, 2026
AMST$0.53+2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| June 30, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| Cash Flows from Operating Activities | |||
| Net Loss | $(3,095,838) | $(3,617,086) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 277,406 | 433,803 | |
| Stock-based compensation expense | 268,127 | 322,037 | |
| Allowance for doubtful accounts | 17,277 | - | |
| Impairment of capitalized software | - | 90,869 | |
| Forfeiture of accrued director compensation | - | (200,000) | |
| Changes in operating assets and liabilities which used cash: | |||
| Accounts receivable | (25,662) | 23,719 | |
| Prepaid expenses and other current assets | (5,349) | 309,389 | |
| Accounts payable | 25,080 | (23,494) | |
| Accrued compensation | 395,402 | 209,813 | |
| Deferred revenue | 80 | 36,745 | |
| Other accrued liabilities | (3,240) | (41,043) | |
| Net cash and cash equivalents used in operating activities | (2,146,717) | (2,455,248) | |
| Cash Flows from Investing Activities | |||
| Purchase of property and equipment | (5,721) | - | |
| Investment in capitalized software | (225,098) | (378,300) | |
| Net cash and cash equivalents used in investing activities | (230,819) | (378,300) | |
| Cash Flows from Financing Activities | |||
| Proceeds from the sale of common stock | 2,342,927 | 3,095,950 | |
| Net cash and cash equivalents provided by financing activities | 2,342,927 | 3,095,950 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (34,609) | 262,402 | |
| Cash, cash equivalents, and restricted cash - Beginning of year | 2,433,418 | 2,171,016 | |
| Cash, cash equivalents, and restricted cash - End of year | $2,398,809 | $2,433,418 | |
| RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TO THE BALANCE SHEET: | |||
| Cash and cash equivalents | $2,298,809 | $2,333,418 | |
| Restricted cash, non-current | 100,000 | 100,000 | |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | 2,398,809 | 2,433,418 | |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES: | |||
| Settle restricted stock units through common stock issuance to directors | $400,000 | $399,975 | |
| Issuance of common stock for accrued director compensation | $ | - | $21,890 |
| Issuance of common stock for public offering consulting expenses | $ | - | $655,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.